330 related articles for article (PubMed ID: 26863209)
81. The Role of Bone Morphogenetic Protein Receptor Type 2 (
Devendran A; Kar S; Bailey R; Trivieri MG
Cells; 2022 Nov; 11(23):. PubMed ID: 36497082
[TBL] [Abstract][Full Text] [Related]
82. Serotonin 5-HT2B receptors are required for bone-marrow contribution to pulmonary arterial hypertension.
Launay JM; Hervé P; Callebert J; Mallat Z; Collet C; Doly S; Belmer A; Diaz SL; Hatia S; Côté F; Humbert M; Maroteaux L
Blood; 2012 Feb; 119(7):1772-80. PubMed ID: 22186990
[TBL] [Abstract][Full Text] [Related]
83. Network of MicroRNAs Mediate Translational Repression of Bone Morphogenetic Protein Receptor-2: Involvement in HIV-Associated Pulmonary Vascular Remodeling.
Chinnappan M; Mohan A; Agarwal S; Dalvi P; Dhillon NK
J Am Heart Assoc; 2018 Feb; 7(5):. PubMed ID: 29478969
[TBL] [Abstract][Full Text] [Related]
84. Bone morphogenetic protein signaling in vascular disease: anti-inflammatory action through myocardin-related transcription factor A.
Wang D; Prakash J; Nguyen P; Davis-Dusenbery BN; Hill NS; Layne MD; Hata A; Lagna G
J Biol Chem; 2012 Aug; 287(33):28067-77. PubMed ID: 22718766
[TBL] [Abstract][Full Text] [Related]
85. AntagomiR directed against miR-20a restores functional BMPR2 signalling and prevents vascular remodelling in hypoxia-induced pulmonary hypertension.
Brock M; Samillan VJ; Trenkmann M; Schwarzwald C; Ulrich S; Gay RE; Gassmann M; Ostergaard L; Gay S; Speich R; Huber LC
Eur Heart J; 2014 Dec; 35(45):3203-11. PubMed ID: 22450430
[TBL] [Abstract][Full Text] [Related]
86. BMPR2 gene therapy for PAH acts via Smad and non-Smad signalling.
Harper RL; Reynolds AM; Bonder CS; Reynolds PN
Respirology; 2016 May; 21(4):727-33. PubMed ID: 26809239
[TBL] [Abstract][Full Text] [Related]
87. Regulation of the Methylation and Expression Levels of the BMPR2 Gene by SIN3a as a Novel Therapeutic Mechanism in Pulmonary Arterial Hypertension.
Bisserier M; Mathiyalagan P; Zhang S; Elmastour F; Dorfmüller P; Humbert M; David G; Tarzami S; Weber T; Perros F; Sassi Y; Sahoo S; Hadri L
Circulation; 2021 Jul; 144(1):52-73. PubMed ID: 34078089
[TBL] [Abstract][Full Text] [Related]
88. Involvement of BMPR2 in the protective effect of fluoxetine against monocrotaline-induced endothelial apoptosis in rats.
Wang Y; Zhang XH; Wang HL
Can J Physiol Pharmacol; 2011 May; 89(5):345-54. PubMed ID: 21619414
[TBL] [Abstract][Full Text] [Related]
89. Increased susceptibility to pulmonary hypertension in heterozygous BMPR2-mutant mice.
Song Y; Jones JE; Beppu H; Keaney JF; Loscalzo J; Zhang YY
Circulation; 2005 Jul; 112(4):553-62. PubMed ID: 16027259
[TBL] [Abstract][Full Text] [Related]
90. 5-HT
Chaturvedi S; Misra DP; Prasad N; Rastogi K; Singh H; Rai MK; Agarwal V
Int J Rheum Dis; 2018 Dec; 21(12):2128-2138. PubMed ID: 30207074
[TBL] [Abstract][Full Text] [Related]
91. Novel Advances in Modifying BMPR2 Signaling in PAH.
Dannewitz Prosseda S; Ali MK; Spiekerkoetter E
Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33374819
[TBL] [Abstract][Full Text] [Related]
92.
Song J; Hinderhofer K; Kaufmann LT; Benjamin N; Fischer C; Grünig E; Eichstaedt CA
Genes (Basel); 2020 Oct; 11(10):. PubMed ID: 33036198
[TBL] [Abstract][Full Text] [Related]
93. BMPR2 mutations influence phenotype more obviously in male patients with pulmonary arterial hypertension.
Liu D; Wu WH; Mao YM; Yuan P; Zhang R; Ju FL; Jing ZC
Circ Cardiovasc Genet; 2012 Oct; 5(5):511-8. PubMed ID: 22923421
[TBL] [Abstract][Full Text] [Related]
94. Hepatic Shunting of Eggs and Pulmonary Vascular Remodeling in Bmpr2(+/-) Mice with Schistosomiasis.
Crosby A; Soon E; Jones FM; Southwood MR; Haghighat L; Toshner MR; Raine T; Horan I; Yang P; Moore S; Ferrer E; Wright P; Ormiston ML; White RJ; Haight DA; Dunne DW; Morrell NW
Am J Respir Crit Care Med; 2015 Dec; 192(11):1355-65. PubMed ID: 26308618
[TBL] [Abstract][Full Text] [Related]
95. Bone morphogenetic protein receptor type 2 mutations, clinical phenotypes and outcomes of Japanese patients with sporadic or familial pulmonary hypertension.
Kabata H; Satoh T; Kataoka M; Tamura Y; Ono T; Yamamoto M; Huqun ; Hagiwara K; Fukuda K; Betsuyaku T; Asano K
Respirology; 2013 Oct; 18(7):1076-82. PubMed ID: 23675998
[TBL] [Abstract][Full Text] [Related]
96. Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension.
Girerd B; Montani D; Eyries M; Yaici A; Sztrymf B; Coulet F; Sitbon O; Simonneau G; Soubrier F; Humbert M
Respir Res; 2010 Jun; 11(1):73. PubMed ID: 20534176
[TBL] [Abstract][Full Text] [Related]
97. Rescuing the BMPR2 signaling axis in pulmonary arterial hypertension.
West J; Austin E; Fessel JP; Loyd J; Hamid R
Drug Discov Today; 2014 Aug; 19(8):1241-5. PubMed ID: 24794464
[TBL] [Abstract][Full Text] [Related]
98. Smooth muscle protein 22alpha-mediated patchy deletion of Bmpr1a impairs cardiac contractility but protects against pulmonary vascular remodeling.
El-Bizri N; Wang L; Merklinger SL; Guignabert C; Desai T; Urashima T; Sheikh AY; Knutsen RH; Mecham RP; Mishina Y; Rabinovitch M
Circ Res; 2008 Feb; 102(3):380-8. PubMed ID: 18079409
[TBL] [Abstract][Full Text] [Related]
99. Somatic chromosome abnormalities in the lungs of patients with pulmonary arterial hypertension.
Aldred MA; Comhair SA; Varella-Garcia M; Asosingh K; Xu W; Noon GP; Thistlethwaite PA; Tuder RM; Erzurum SC; Geraci MW; Coldren CD
Am J Respir Crit Care Med; 2010 Nov; 182(9):1153-60. PubMed ID: 20581168
[TBL] [Abstract][Full Text] [Related]
100. Truncating and missense BMPR2 mutations differentially affect the severity of heritable pulmonary arterial hypertension.
Austin ED; Phillips JA; Cogan JD; Hamid R; Yu C; Stanton KC; Phillips CA; Wheeler LA; Robbins IM; Newman JH; Loyd JE
Respir Res; 2009 Sep; 10(1):87. PubMed ID: 19785764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
